Improving control of hypertension by an integrated approach - Results of the 'Manage it well!' programme

Journal of Hypertension

Volumn 23, Issue 1, 2005, Pages 203-211

  Szirmai, Laszlo A ^a,b   Arnold, Csaba ^a   Farsang, Csaba ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b Department of Scientific Research   (Hungary)

Author keywords

Adherence; Compliance; Control rate; Diastolic blood pressure; Home blood pressure measurement; Hypertension; Responder; Systolic blood pressure

Indexed keywords

TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; FEMALE; FOLLOW UP; HEALTH CARE; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 12344252773     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200501000-00031     Document Type: Article

References (35)

1. Farsang CS, Alföldi S, Barna I, Finta PE, Kapocsi J, Kishegyi J, et al., on behalf of the ECHP team. Effective Control of Hypertension Project of the Hungarian Society of Hypertension. Curr Hypertens Rep (Hungarian edition) 2002; 1:201-207.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. I: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
3. MacMahon S, Neal B, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectiveiy designed overviews of randomized trials. Lancet 2000; 356:1955-1964.
4. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755-1762.
6. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157:2413-2446.
7. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
8. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11:213-220.
9. Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation - Regional and Global) project. Am Heart J 1999; 138:231-237.
10. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36:594-599.
11. Mancia G, Giannattasio C, Grassi G. Current antihypertensive treatment: can we do better? Am J Hypertens 1999; 12:131-138.
12. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
13. Haynes BR, McRibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348:383-386.
14. McInnes GT. Integrated approaches to management of hypertension: promoting treatment acceptance. Am Heart J 1999; 138:252-255.
15. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, et al., for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001; 37:12-18.
16. Logan AG, Irvine MJ. Compliance, labeling and hypertension. In: Swales JD (editor): Textbook of hypertension. London, Edinburgh, Boston, Melbourne: Blackwell Scientifc Publications; 1994. pp. 1267-1282.
17. Alderman MH. Barriers to blood pressure control. Am J Hypertens 1999; 12:1268-1269.
18. Williams GH. Assessing patient wellness: new perspectives on quality of life and compliance. Am J Hypertens 1998; 11:186-191.
19. Miller N, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call for action. A statement for healthcare professionals. Circulation 1997; 95:1085-1090.
20. Sackett DL, Snow JC. The magnitude of adherence and nonadherence. In: Haynes RB, Taylor DW, Sackett DL (editors): Compliance in health care. Baltimore: John Hopkins University Press; 1979. pp. 11-22.
21. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19:335-341.
22. Freis ED. Improving treatment effectiveness in hypertension [commentary]. Arch Int Med 1999; 159:2517-2521.
23. Mallion JM, Baguet JP, Siehe JP, Tremel F, Gaudemaris R. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens 1997; 16:75-80.
24. Nessmann DG, Carnahan JE, Nugent CA. Increasing compliance. Patient-operated hypertension groups. Arch Int Med 1980; 140:1427-1430.
25. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000; 35:23-26.
26. Ashida T, Sugiyama T, Okuno S, Ebihara A, Fujii J. Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs. Hypertens Res 2000; 23:21-24.
27. Kjeligren KI, Ahlner J, Saeljoe R. Taking antihypertensive medication - controlling or co-operating with patients? Int J Cardiol 1995; 47: 257-268.
28. Haynes RB, Sackett DL, Gibson ES, Taylor DW, Hackett BC, Roberts RS, Johnson AL Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1:1265-1268.
29. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Int Med 1993; 153:1863-1868.
30. Repine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al., for the INVEST investigators. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a rqandomized controlled trial. JAMA 2003; 290:2805-2816.
31. de la Figuera M, Rodriguez JAS, Boero R, for the THOR Investigators. Duration of trandolapril antihypertensive effect 24 and 48 hours from last dose. Clin Drug Invest 1999; 17:43-50.
32. Ayman D, Goldshine AD. Blood pressure determinations by patients with essential hypertension: differences between clinic and home readings. Am J Med Sci 1940; 200:465-474.
33. Pickering T. The influence of daily activity on ambulatory blood pressure. Am Heart J 1988; 116:1141-1145.
34. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions and miunderstandings. What should we do next? J Hypertens 1999; 34:267-272.
35. Coats AJ, Conway J, Somers VK, Isea JE, Sleight P. Ambulatory pressure monitoring in the assessment of anti-hypertensive therapy. Cardiovasc Drugs Ther 1989; 3:303-311.